

# Clinical trials of Enoxaparin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>Enoxaparin vs placebo</b>			
<a href="#">AMI-SK , 2002</a> n=253/243 follow-up: 30 d	Enoxaparin 30 mg IV bolus, 1 mg/kg for 38 d versus placebo	patients with evolving myocardial infarction, Age >=18 y, STEMI	Parallel groups Double-blind
<b>Enoxaparin vs UFH</b>			
<a href="#">ASSENT 3 Plus , 2003</a> n=818/821 follow-up: 30 d	Enoxaparin 1 mg/kg BID, <=7d versus UFH 60 IU/kg, then 12 IU/kg per h for >=3d	patients with ST-elevation myocardial infarction	Parallel groups open
<a href="#">ASSENT 3 , 2001</a> n=2040/2038 follow-up: 65279;30 d	65279;Enoxaparin 1 mg/kg BID, <=7d versus UFH 65279;60 U/kg bolus, then 12 IU/kg per h for 48 h	patients with acute myocardial infarction	Parallel groups open
<a href="#">Baird , 2002</a> n=149/151 follow-up: 90 d	Enoxaparin 40 mg TID, 4 d versus UFH 5000 IU bolus, then 30 000 IU over 24 h for 4d	patients receiving fibrinolytic therapy following acute myocardial infarction	Parallel groups 90-min TIMI flow
<a href="#">ENTIRE-TIMI 2 , 2002</a> n=160/82 follow-up: 30 d	Enoxaparin 1 mg/kg BID, <=8d versus UFH 60 IU/kg, then 12 IU/kg per h for >=3d	Patients with ST-elevation MI presenting <6 hours from symptom onset were	Parallel groups open
<a href="#">HART II , 2001</a> n=200/200 follow-up: 57 d	Enoxaparin 1 mg/kg BID, <=3d versus UFH 40005000 IU bolus, then 15 IU/kg per hour for >=3d	patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI	Parallel groups open

More details and results :

- antithrombotics for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q36>
- heparin (UFH or LMWH) for acute myocardial infarction in patients eligible to receive fibrinolytic therapy at <http://www.trialresultscenter.org/go-Q308>

## References

### AMI-SK, 2002:

Simoons M, Krzemiska-Pakula M, Alonso A, Goodman S, Kali A, Loos U, Gosset F, Louer V, Bigonzi F Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-90 [12175665]

### ASSENT 3 Plus, 2003:

Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Mkiyrvi M, Verheugt F, Van de Werf F Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42 [12847070]

### ASSENT 3, 2001:

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13 [11530146]

### Baird, 2002:

Baird SH, Menown IB, McBride SJ, Trouton TG, Wilson C Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-32 [11969277]

### ENTIRE-TIMI 2, 2002:

Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf F Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9 [11940541]

### HART II, 2001:

Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52 [11489769]

## 2 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>enoxaparin vs UFH</b>			
<b>THE-PRINCE (Kleber) , 2003</b> n=164/169 follow-up:	enoxaparin 40mg once daily for 10+/-2 days versus UFH 5000 IU 3 times daily for 10+/-2 days	patients hospitalized for severe respiratory disease or heart failure (NYHA III, IV)	Parallel groups open germany

More details and results :

- antithrombotics for heart failure in patients hospitalized for heart failure at <http://www.trialresultscenter.org/go-Q72>

## References

### THE-PRINCE (Kleber), 2003:

Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, , Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21. [[12679756](#)] [10.1067/mhj.2003.189](#)

## 3 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
<b>enoxaparin vs unfractionated heparin</b>			
<b>RESCUE</b> [NCT00077818] n=NA follow-up: 30 days	Enoxaparin versus unfractionated heparin	patients diagnosed with acute coronary syndrome in the emergency department	Parallel groups open
<b>enoxaparin vs tinzaparin</b>			
<b>EVET , 2005</b> n=220/218 follow-up: 30 days	enoxaparin, 100 IU/kg subcutaneously twice daily +aspirin for 7 days versus tinzaparin, 175 IU/kg subcutaneously once daily +aspirin for 7 days	patients with non-ST-segment elevation acute coronary syndromes	Parallel groups open
<b>enoxaparin vs UFH (on top of aspirin)</b>			
<b>ESSENCE , 1997</b> n=1607/1564 follow-up: 14 days (30 days)	enoxaparin 1mg/kg, twice daily during 48h-8days versus continuous intravenous unfractionated heparin	patients with angina at rest or nonQ-wave myocardial infarction	Parallel groups Double blind United states, Canada, South America, Europe
<b>INTERACT , 2006</b> n=380/366 follow-up: 30 days (2.5y)	enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) versus intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin)	high-risk patients with ACS receiving aspirin and eptifibatide	Parallel groups open Canada
<b>SYNERGY , 2005</b> [NCT00043784] n=4993/4985 follow-up: 30 days	Enoxaparin 1 mg/kg twice daily versus unfractionated heparin	high-risk patients with acute coronary syndromes	Parallel groups open 12 countries

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>TIMI 11 B (long term) , 1998</b> n=1953/1957 follow-up: 43 days	enoxaprin during both the acute phase (IV) and outpatient phase (SC) versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	double blind North America, South America,
<b>TIMI 11 B (short term) , 1998</b> n=1953/1957 follow-up: 8 days (43 days)	enoxaprin during both the acute phase and outpatient phase versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	Parallel groups double blind North America, South America,

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antithrombotics for acute coronary syndrome in unstable angina at <http://www.trialresultscenter.org/go-Q35>
- heparin (UFH or LMWH) for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q171>

## References

### **RESCUE, :**

### **EVET, 2005:**

Katsouras C, Michalis LK, Papamichael N, Adamides K, Naka KK, Nikas D, Goudevenos JA, Sideris DA Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005;150:385-91 [16169312]

### **ESSENCE, 1997:**

Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52 [9250846] 10.1056/NEJM199708143370702

### **INTERACT, 2006:**

Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 2006;151:373-9 [16442903]

Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44 [12538422]

### **SYNERGY, 2005:**

Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005 Nov 23;294:2594-600 [16304073]

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. *Am Heart J* 2006;152:1042-50 [17161049]

Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hoc Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54 [15238590]

**TIMI 11 B (long term), 1998:**

**TIMI 11 B (short term), 1998:**

Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. *Circulation* 1999 Oct 12;100:1593-601 [10517729]

## 4 thrombosis prevention

CT

Trial	Treatments	Patients	Trials design and methods
<b>enoxaparin vs control</b>			
<b>Canata , 2003</b> n=18/18 follow-up: 6 days	enoxaparin sc daily (dose not specified) versus no treatment	ACL reconstruction for symptomatic ACL-deficient knees	Parallel groups Italy
<b>enoxaparin vs no treatment</b>			
<b>Ho [43]</b> n=134/169	Enoxaparin 4000 anti-Xa units versus No treatment	-	Open
<b>Warwick , 1995</b> n=78/78 follow-up: 8-10 days	enoxaparin 4000x1 + elastic stockings versus no treatment + elastic stockings	Elective hip	open
<b>enoxaparin vs placebo</b>			
<b>LIFENOX , 2011</b> [NCT00622648] n=4171/4136 follow-up: 30 days	subcutaneous enoxaparin 40 mg daily for 104 days versus placebo	hospitalized, acutely ill medical patients	Parallel groups double-blind China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Lederle , 2006 n=140/140 follow-up: 90 days	Enoxaparin 40 mg once daily, until hospital discharge versus placebo	Hospitalization in general medical unit	Parallel groups double blind
MEDENOX , 1999 n=291/288 follow-up: 6-14 days	Enoxaparin 20 mg or 40 mg once daily, 614 days versus placebo	Acute decompensated chronic obstructive pulmonary disease with mechanical ventilation	Parallel groups double blind
Kalodiki , 1996 n=13/14 follow-up: discharge (8-12 days )	enoxaparin 4000x1 versus Placebo	Elective hip	double blind
LeGagneux , 1987 n=44/45	Enoxaparin 6000 anti-Xa units versus 65279;Placebo	prostatectomy surgery	65279;Blind
Leclerc , 1991 n=65/64 follow-up: 14 days	Enoxaparin 3000 x2 versus Placebo	Knee	double blind
Samama , 1997 n=85/85 follow-up: 8-12 days	enoxaparin 4000x1+elastic stockings versus Placebo+elastic stockings	Elective hip	double blind
Turpie , 1986 n=50/50 follow-up: 14 days or discharge	Enoxaparin 3000 x2 versus Placebo	Elective hip	double blind
Agnelli , 1998 n=153/154 follow-up: 30 days	Enoxaparin, 40 mg/d subcutaneously within 24 hours postoperatively plus compression stockings for $\geq 7$ days versus compression stockings + placebo	Elective neurosurgery, 18 years or older, without excess bleeding risk	
Melon , 1987 n=67/63 follow-up: NA	Enoxaparin, 20 mg/d subcutaneously 18-24 hours postoperatively for 10 days versus placebo	Neurosurgery, adult, 45-90 kg of weight, without excess bleeding risk	
<b>enoxaparin vs Dextran</b>			
DES Group , 1991 n=120/126	Enoxaparin versus Dextran	Elective hip	
<b>out of hospital Enoxaparin vs standard prophylaxis</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Bergqvist , 1996 n=117/116	65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 30 days versus 65279;Enoxaparin 40 mg once a day for 10-11 days	65279;THR	
Planes , 1996 n=90/89	65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 35 days versus Enoxaparin 40 mg once a day for 13-15 days	THR	
Comp , 2001 n=441/432	65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 27-29 days versus Enoxaparin 30 mg twice a day for 7-10 days	THR or TKR	
<b>enoxaparin vs UFH</b>			
Bergmann and Neuhart , 1996 n=NA follow-up: 10 days	enoxaparin 20 mg once daily for 10 days versus unfractionated heparin (UFH) 5000 IU twice daily	elderly in-patients bedridden for an acute medical illness	Parallel groups double-blind
Lechler , 1996 n=NA follow-up: 7 days	enoxaparin 40 mg versus unfractionated heparin (Ca-heparin), 3 x 5,000 U)	hospitalized medical patients	Parallel groups double-blind
Kleber , 2003 n=NA follow-up: 10 +/- 2 days	enoxaparin 40 mg once daily for 10 +/- 2 days versus UFH 5000 IU 3 times daily for 10 +/- 2 days	severe respiratory disease or heart failure	Parallel groups open Germany
<b>enoxaparin vs Unfractionated heparin</b>			
Samama 2 , 1988 n=127/123 follow-up: 7 days	Enoxaparin 4000 versus UFH 15 000 units	General surgery	Open

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Samama 1 , 1988 n=168/167 follow-up: 7 days	Enoxaparin 2000 versus UFH 15 000 units	General surgery	Open
Levine , 1991 n=333/332	Enoxaparin versus Unfractionated heparin	Elective hip	
Samama 3 , 1988 n=160/147 follow-up: 7 days	Enoxaparin 6000 versus UFH 15 000 units	General surgery	Open
Planes , 1988 n=124/113	Enoxaparin versus Unfractionated heparin	Elective hip	
Kaaja , 1992 n=37/31	Enoxaparin 2000 anti Xa units versus UFH 10 000 units	Gynaecological surgery	Blind
Gazzaniga (ISG) , 1993 n=561/561	Enoxaparin 2000 anti Xa units versus UFH 10 000 units	General and vascular surgery	Open
Nurmohamed , 1995 n=737/734	Enoxaparin 2000 anti Xa units versus UFH 15 000 units	General surgery	Blind
McLeod (Canadian) , 1995 n=674/675	Enoxaparin 4000 anti Xa units versus UFH 15 000 units	Colorectal surgery	Blind
Gonzalez , 1996 n=84/82	Bemiparin 2500 anti Xa units versus UFH 10 000 units	Abdominal surgery	Blind
ENOXACAN , 1997 n=555/560	Enoxaparin 4000 anti Xa units versus UFH 15 000 units	Abdominopelvic surgery	Blind

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective major knee surgery at <http://www.trialresultscenter.org/go-Q38>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>
- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>



- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antithrombotics for thrombosis prevention in urologic surgery at <http://www.trialresultscenter.org/go-Q93>
- antithrombotics for thrombosis prevention in gynaecological surgery at <http://www.trialresultscenter.org/go-Q94>
- antithrombotics for thrombosis prevention in abdominal surgery at <http://www.trialresultscenter.org/go-Q96>
- antithrombotics for thrombosis prevention in neurosurgery at <http://www.trialresultscenter.org/go-Q99>
- antithrombotics for thrombosis prevention in arthroscopy at <http://www.trialresultscenter.org/go-Q150>
- heparin (UFH or LMWH) for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q189>
- LMWH for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q190>
- UFH for thrombosis prevention in urologic surgery at <http://www.trialresultscenter.org/go-Q194>
- heparin (UFH or LMWH) for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q195>
- LMWH for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q196>
- heparin (UFH or LMWH) for thrombosis prevention in neurosurgery at <http://www.trialresultscenter.org/go-Q197>
- LMWH for thrombosis prevention in neurosurgery at <http://www.trialresultscenter.org/go-Q198>
- LMWH for thrombosis prevention in gynaecological surgery at <http://www.trialresultscenter.org/go-Q200>
- LMWH for thrombosis prevention in abdominal surgery at <http://www.trialresultscenter.org/go-Q202>
- LMWH for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q719>

## References

### Canata, 2003:

Canata GL, Chiey A. Prevention of venous thromboembolism after ACL reconstruction: a prospective, randomized study.(International Society of Arthroscopy, Knee Surgery and OrthopaedicSports Medicine) 2003; Vol. Poster 71-2003.

### Ho [43], :

Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum 1999;42:196-202; discussion 202-3 [10211496]

### Warwick, 1995:

Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ, Brookes S Perioperative low-molecular-weight heparin. Is it effective and safe. J Bone Joint Surg Br 1995 Sep;77:715-9 [7559695]

**LIFENOX, 2011:**

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med* 2011 Dec 29;365:2463-72 [22204723] 10.1056/NEJMoa1111288

**Lederle, 2006:**

Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW, Eid AA, Sebastian J, Stasek JE Jr, Fye CL The prophylaxis of medical patients for thromboembolism pilot study. *Am J Med* 2006;119:54-9 [16431185]

**MEDENOX, 1999:**

Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med* 1999;341:793-800 [10477777]

**Kalodiki, 1996:**

Kalodiki EP, Hoppensteadt DA, Nicolaides AN, Fareed J, Gill K, Regan F, al-Kutoubi A, Cunningham DA, Birch R, Harris N, Hunt D, Johnson J, Marx C Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. *Int Angiol* 1996 Jun;15:162-8 [8803642]

**LeGagneux , 1987:**

Le Gagneux F, Steg A, Le Guillou M. imag Subcutaneous enoxaparine (Lovenox) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP) *Thromb Haemost* 1987; 58: 116 (Abstract).

**Leclerc, 1991:**

Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Bourgouin J Prevention of deep vein thrombosis after major knee surgery—a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. *Thromb Haemost* 1992 Apr 2;67:417-23 [1321509]

**Samama, 1997:**

Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. *Br J Anaesth* 1997 Jun;78:660-5 [9215015]

**Turpie, 1986:**

Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *N Engl J Med* 1986 Oct 9;315:925-9 [3531851]

**Agnelli, 1998:**

Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med* 1998;339:80-5 [9654538]

**Melon, 1987:**

Melon E, Keravel Y, Gaston A, Huet Y, Combes S, and the NEURONOX groupj Deep venous thrombosis prophylaxis by low molecular weight heparin in neurosurgical patients [abstract *Anesthesiology*. 1987;75:A214

**DES Group , 1991:****Bergqvist, 1996:**

Bergqvist D, Benoni G, Bjrgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N Engl J Med* 1996;335:696-700 [8703168]

**Planes, 1996:**

Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. *Lancet* 1996;348:224-8 [8684199]

**Comp, 2001:**

Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jov M Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *J Bone Joint Surg Am* 2001;83-A:336-45 [11263636]

**Bergmann and Neuhart, 1996:**

Bergmann JF, Neuhart E A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. *Thromb Haemost* 1996;76:529-34 [8902991]

**Lechler, 1996:**

Lechler E, Schramm W, Flosbach CW The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. *Haemostasis* 1996;26 Suppl 2:49-56 [8707167]

**Kleber, 2003:**

Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J* 2003;145:614-21 [12679756] 10.1067/mhj.2003.189

**Samama 2, 1988:**

Samama M, Bernard P, Bonnardot JP, Combe-Tanzali S, Lanson Y, Tissot E Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. *Br J Surg* 1988;75:128-31 [2832030]

Samama MM Prevention of postoperative thromboembolism in general surgery with enoxaparin. *Eur J Surg Suppl* 1994;:31-3 [7519086]

**Samama 1, 1988:**

Samama M, Bernard P, Bonnardot JP, Combe-Tanzali S, Lanson Y, Tissot E Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. *Br J Surg* 1988;75:128-31 [2832030]

Samama MM Prevention of postoperative thromboembolism in general surgery with enoxaparin. *Eur J Surg Suppl* 1994;:31-3 [7519086]

Samama M, Combe S Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane). *Acta Chir Scand Suppl* 1990;556:91-5 [1963022]

**Levine , 1991:**

**Samama 3, 1988:**

Samama M, Bernard P, Bonnardot JP, Combe-Tanzali S, Lanson Y, Tissot E Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. *Br J Surg* 1988;75:128-31 [2832030]

Samama MM Prevention of postoperative thromboembolism in general surgery with enoxaparin. *Eur J Surg Suppl* 1994;:31-3 [7519086]

**Planes , 1988:**

Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thromb Haemost* 1988 Dec 22;60:407-10 [2853459]

**Kaaja, 1992:**

**Gazzaniga (ISG), 1993:**

Creperio G, Marabini M, Ciocia G, Bergonzi M, Fincato M [Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery] *Minerva Chir* 1990;45:1101-6 [2177861]

Creperio G, Marabini M, Ciocia G, Bergonzi M, Fincato M [Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery] *Minerva Chir* 1990;45:1101-6 [2177861]

**Nurmohamed, 1995:**

**McLeod (Canadian), 1995:**

**Gonzalez, 1996:**

**ENOXACAN, 1997:**

## 5 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
<b>Enoxaparin vs acenocoumarol</b>			
Veiga , 2000 n=50/50 follow-up: 6-9 mo	UFH, APTT 1.52.0d followed by Enoxaparin 4,000 IU qd versus UFH, APTT 1.52.0d followed by Acenocoumarol target INR 2-3	patients with objective diagnosis of DVT by Venography	open
<b>Enoxaparin vs coumarin</b>			
Gonzlez-Fajardo , 2008 n=85/80 follow-up: 1y, 5y	long-term anticoagulant treatment with enoxaparin during at least 3 months versus long-term anticoagulant treatment with coumarin during at least 3 months	patients with symptomatic, unilateral, first-episode DVT	Parallel groups open, blind assessment Spain
<b>extended enoxaparin vs standard treatment</b>			
Cesarone , 2003 n=NA follow-up: 3 months	Enoxaparin 100UL/Kg twice daily for 3 months versus coumadin (target INR 3) for 3 months.	patients with cancer with DVT	Parallel groups NA
Deitcher , 2006 n=NA follow-up: 12 months	Enoxaparin 1mg/kg twice daily for 5 days followed by 1-1.5mg/kg daily for 175 days versus Enoxaparin 1mg/kg twice daily for 5 days followed by warfarin (target INR 2-3) for a total of 180 days	patients with cancer with DVT and/or PE	Parallel groups none

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Meyer , 2002 n=NA follow-up: 3 months	Enoxaparin 1.5 mg/kg daily for 3 monthsmag versus Enoxaparin 1.5 mg/kg daily for 4 days followed by warfarin (target INR 2-3) for 3 months	patients with cancer (solid or hematological; active or in remission but on treatment); with pulmonary embolism and/or DVT and a minimum life expectancy of 3 months	Parallel groups outcome assessment blinded
<b>Enoxaparin vs warfarin</b>			
Deitcher , 2003 n=51/30 follow-up: 6 mo	LMWH: 1a, 1 mg/kg q12h; 1b, 1 mg/kg qd12h followed by Enoxaparin 1a: 1 mg/kg qd; 1b: 1.5 mg/kg qd versus LMWH, 1 mg/kg q12h followed by Warfarin target INR 2-3	patients with objective diagnosis of DVT	open
Meyer , 2002 n=71/58 follow-up: 3 mo	LMWH, 1.5 mg/kg qd followed by Enoxaparin 1.5 mg/Kg qd versus LMWH, 1.5 mg/kg qd followed by Warfarin target INR 2-3	patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography	open
Gonzalez-Fajardo , 1999 n=93/92 follow-up: 9 mo	LMWH, 4,000 IU bid followed by Enoxaparin 4,000 IU qd versus UFH followed by Warfarin target INR 2-3	patients with objective diagnosis of DVT by Venography	Parallel groups open
Pini , 1994 n=93/94 follow-up: 9 mo	UFH, APTT 1.31.9 followed by Enoxaparin 4,000 IU qd versus UFH, APTT 1.31.9 followed by Warfarin target INR 2-3.5	patients with objective diagnosis of DVT by Venography (diagnosed by strain-gauge plethysmography plus D-dimer latex assay and confirmed by venography)	open
<b>once daily enoxaparin vs twice daily enoxaparin</b>			
Merli , 2001 n=298/312 follow-up:	enoxaparin 1.5 mg/kg body weight once daily versus S.c. enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily	patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)	Parallel groups double blind Europe, United States of America and Australia, image/pj
<b>once daily enoxaparin vs UFH</b>			
Merli (once daily vs UFH) , 2001 n=298/290 follow-up: 3 months	Initial therapy with enoxaparin 1.5 mg/kg body weight once daily versus Initial therapy with dose-adjusted intravenous unfractionated heparin	patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)	Parallel groups partially blinded Europe, United States of America and Australia, image/pj
<b>Enoxaparin vs unfractionated heparin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Simonneau et al , 1993 n=67/67 follow-up: 3 Months	Enoxaparin Subcutaneous twice daily for 0 Days, 100 U/kg BID versus unfractionated heparin intravenous APPTx1.5-2.5	-	

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>
- LMWH for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q203>
- heparin (UFH or LMWH) for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q204>

## References

### Veiga, 2000:

Veiga F, Escrib A, Maluenda MP, Lpez Rubio M, Margalet I, Lezana A, Gallego J, Ribera JM Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. *Thromb Haemost* 2000;84:559-64 [[11057850](#)]

### Gonzlez-Fajardo, 2008:

Gonzlez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. *J Vasc Surg* 2008;48:953-9 [[18639417](#)]

### Cesarone, 2003:

Cesarone MR, Ledda A, Nicolaidis A, Belcaro G, Geroulakos G.s=40 Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients *Supplement to Circulation*. 2003; Vol. 108, issue 17:Abstract 2875.

### Deitcher, 2006:

Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. *Clin Appl Thromb Hemost* 2006;12:389-96 [[17000884](#)]

### Meyer, 2002:

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med* 2002;162:1729-35 [[12153376](#)]

### Deitcher, 2003:

Deitcher SR, Kessler MG, Lyons RM., imag Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period [abstract].s-e *Blood* 2003; 102:322a

### Meyer, 2002:

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35 [[12153376](#)]

**Gonzalez-Fajardo, 1999:**

Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutierrez V, Vaquero C Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999;30:283-92 [[10436448](#)]

Gonzalez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. J Vasc Surg 2008 Oct;48:953-9 [[18639417](#)]

**Pini, 1994:**

Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-7 [[7831650](#)]

**Merli, 2001:**

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202 [[11177331](#)]

**Merli (once daily vs UFH), 2001:**

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001 Feb 6;134:191-202 [[11177331](#)]

**Simonneau et al , 1993:**

Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993 Jul 12;153:1541-6 [[8391792](#)]

## 6 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>enoxaparin vs UFH</b>			
<a href="#">ATOLL , 2010</a> n=450/460 follow-up: 30 days	IV enoxaparin versus UFH	patients undergoing PCI for acute STEMI	Parallel groups open Austria, France, Germany, and US
<a href="#">Brieger</a> n=346/234 follow-up:	enoxaparin versus unfractionated heparin	patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)	

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>CRUISE , 2003</b> n=129/132 follow-up: 2,7 +30 days	Enoxaparin 0.75 mg/kg bolus versus 65279;UFH 60 IU/kg bolus, then titrated to ACT >200	Urgent or elective PCI	Parallel groups open
<b>Drozd , 2001</b> n=50/50 follow-up: 24hrs, 30 days	65279;Enoxaparin 1 mg/kg bolus versus UFH 100 IU/kg bolus	PCI for stable angina	
<b>Dudek , 2000</b> n=200/200 follow-up: 3 days	Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT >300	PCI	
<b>Dudek b (enox alone) , 2000</b> n=NA follow-up:	Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT >300	PTCA complex lesionsCI	
<b>Galeote , 2001</b> n=50/49 follow-up:	Enoxaparin 0.75 mg/kg bolus versus UFH 70 U/kg bolus, then titrated to ACT >200	PTCA patients with stable/unstable angina or AMI	
<b>Rabah , 1999</b> n=30/30 follow-up:	Enoxaparin 1 mg/kg bolus versus 65279;UFH 10,000 IU bolus, then titrated to ACT >300	PCI for stable angina	Parallel groups open
<b>STEEPLE , 2006</b> [NCT00077844] n=NA follow-up:	enoxaparin (0.5 or 0.75 mg per kilogram of body weight) versus unfractionated heparin (adjusted for activated clotting time)	elective percutaneous coronary intervention.	Parallel groups open
<b>enoxaparin+abciximab vs UFH</b>			
<b>Dubek b (+abciximal) , 2001</b> n=NA	Enoxaparin 0.75 mg/kg bolus + abciximab versus UFH titrated to ACT >300	-	
<b>enoxaparin vs unfractionated heparin</b>			
<b>STREAM ongoing</b> [NCT00882635] n=NA follow-up:	Enoxaparin versus Unfractionated Heparin	St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention	

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>



- antithrombotics for percutaneous coronary intervention in MI patients undergoing primary PCI at <http://www.trialresultscenter.org/go-Q291>
- anticoagulant for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q388>
- anticoagulant for percutaneous coronary intervention in patients undergoing primary PCI at <http://www.trialresultscenter.org/go-Q457>

## References

### ATOLL, 2010:

#### Brieger, :

Brieger D, Collet JP, Silvain J, Landivier A, Barthlmy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2011;77:182-90 [20578166] [10.1002/ccd.22674](https://doi.org/10.1002/ccd.22674)

### CRUISE, 2003:

Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM Safety of concomitant therapy with eptifibatid and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. *J Am Coll Cardiol* 2003;41:20-5 [12570939]

### Drozd, 2001:

Drozd J, Opalinska E, Wojcik J, Madejczyk A. Pag The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina *Kardiol Pol* 2001;55:520524

### Dudek, 2000:

Dudek D, Dabrowski M, Ochala A, Lesaik M, Wnek A, Bryniarski Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions *Am J Cardiol* 2000;86(Suppl 8A):15i. [imag](https://doi.org/10.1016/S0002-8884(00)00151-1)

### Dudek b (enox alone), 2000:

Dudek D, Bartus S, Zymek P, Legutko J, Rzeszutko L, Janion M, Abciximab and enoxaparin administration during elective high-risk PTCA in patients with more than 3 days of ticlopidine pretreatment. *J Am Coll Cardiol* 2000;35(Suppl):91A

### Galeote, 2001:

Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sanchez- Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomised study *Eur Heart J* 2001;22(Suppl):663

### Rabah, 1999:

Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. *Am J Cardiol* 1999;84:1391-5 [10606110]

### STEEPLE, 2006:

Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. *N Engl J Med* 2006;355:1006-17 [16957147]

### Dubek b (+abciximal), 2001:

#### STREAM, :

## 7 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
<b>Enoxaparin vs unfractionated heparin</b>			
<b>PREPIC , 1998</b> n=41/54 follow-up: 2 y	Enoxaparin, 1 mg/kg twice daily, 8-12 days versus Unfractionated heparin: bolus 5000 IU, infusion 500 IU/kg per day	patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism	Factorial plan open
<b>Merli sub group , 2001</b> n=199/88 follow-up: 3 mo	Enoxaparin, 1mg/kg twice daily or 1.5 mg/kg once daily, 5 days versus Unfractionated heparin: according nomogram at local institution	patients with confirmed pulmonary embolism	Parallel groups open 16 countries

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

## References

### PREPIC, 1998:

Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prvention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15 [9459643]

### Merli sub group, 2001:

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilka K Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202 [11177331]

## 8 superficial thrombophlebitis

Trial	Treatments	Patients	Trials design and methods
<b>enoxaparin vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
STENOX (enoxaparin 1.5mg/hg) , 2003 n=NA follow-up:	enoxaparin (s.c. 1.5 mg/kg)for 8-12 days versus placebo	patients with St of at least 5 cm on ultrasonography examination	
Stenox (enoxaparin 40mg) , 2003 n=NA follow-up:	LMWH (enoxaparin) (s.c. 40 mg) for 8-12 days versus placebo.	patients with ST of at least 5 cm on ultrasonography examination	

More details and results :

- antithrombotics for superficial thrombophlebitis in superficial thrombophlebitis of the leg at <http://www.trialresultscenter.org/go-Q218>

## References

**STENOX (enoxaparin 1.5mg/hg), 2003:**

**Stenox (enoxaparin 40mg), 2003:**

A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003;163:1657-63 [12885680]

Entry terms: enoxaparin, Lovenox, Clexane